DS
GLUE icon

David Shaw’s Monte Rosa Therapeutics GLUE Stock Holding History

David Shaw’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.16M Buy
172,053
+105,726
+159% +$2M ﹤0.01% 2563
2026
Q1 		$1.09M Sell
66,327
-19,161
-22% -$366K ﹤0.01% 3382
2025
Q4 		$1.34M Buy
85,488
+35,275
+70% +$475K ﹤0.01% 3349
2025
Q3 		$372K Buy
+50,213
New +$266K ﹤0.01% 4010
2025
Q1 		– Sell
-70,114
Closed -$487K – 4432
2024
Q4 		$487K Buy
70,114
+51,823
+283% +$389K ﹤0.01% 3635
2024
Q3 		$96.9K Sell
18,291
-5,131
-22% -$25.9K ﹤0.01% 4252
2024
Q2 		$87.6K Buy
+23,422
New +$119K ﹤0.01% 4181
2022
Q1 		– Sell
-24,085
Closed -$492K – 5676
2021
Q4 		$492K Sell
24,085
-23,039
-49% -$482K ﹤0.01% 4410
2021
Q3 		$1.05M Buy
+47,124
New +$1.35M ﹤0.01% 3565

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

David Shaw's GLUE Position: Q2 2026 in Review

David Shaw increased its Monte Rosa Therapeutics (GLUE) stake by 159% in Q2 2026, buying an estimated $2M and bringing the position to 172,053 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2563.

David Shaw first reported a position in GLUE in Q3 2021 and has held it in 9 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • David Shaw held 172,053 shares of Monte Rosa Therapeutics worth $4.16M as of Q2 2026.
  • David Shaw bought 105,726 Monte Rosa Therapeutics shares in Q2 2026, an estimated $2M.
  • Monte Rosa Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2563 holding.
  • David Shaw first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.